ADVERTISEMENT

404

Not Found

Is this what you were looking for?

tag pharma fda cancer regulation

Lazarus Drugs
Kate Yandell | Feb 1, 2015 | 8 min read
While some drugs sail through development, others suffer setbacks, including FDA rejections, before reaching the market.
 
Bugs as Drugs to Boost Cancer Therapy
Danielle Gerhard, PhD | Jan 18, 2024 | 7 min read
Bioengineered bacteria sneak past solid tumor defenses to guide CAR T cells’ attacks.
TS Picks: September 8, 2015
Jef Akst | Sep 8, 2015 | 1 min read
Pharma edition
Matthew Disney
A Quest to Drug RNA
Ida Emilie Steinmark, PhD | Sep 8, 2023 | 5 min read
Matthew Disney’s idea of small molecules that target RNA once seemed fanciful. Now, even the pharma industry is pursuing it
The Vaginal Microbiome is Finally Getting Recognized
Hannah Thomasy, PhD, Drug Discovery News | Sep 25, 2023 | 10+ min read
Vaginal dysbiosis has long been a taboo subject, but studying and optimizing the vaginal microbiome could be a game changer for women's health.
FDA Gives Nod to Melanoma Drug
Jef Akst | Sep 8, 2014 | 2 min read
The US Food and Drug Administration last week approved the first of a new type of immunotherapy that aims to pit a patient’s own immune system against her cancer.
Pharma CPR
Brendan Borrell | Dec 1, 2009 | 7 min read
.table { font-family: "Trebuchet MS", Arial, Helvetica, sans-serif; text-align: center; }.drug_table { font-size: 11px; font-family: "Trebuchet MS", Arial, Helvetica, sans-serif; }.drug_table td { padding: 2px; border-left: 1px solid #CCCCCC; }.drug_table tr.even td, .drug_table thead tr td { font-weight: bold; }.drug_table thead tr td { font-size: 13px; color: #62A476; }.drug_table tr.even td { background: #F8E4B9; }.drug_table tr.odd td { bac
PARP Inhibitors Are Improving the Outlook of Hard-to-Treat Cancers
Vicki Brower | Apr 1, 2018 | 9 min read
With three recent FDA approvals, and a number of Phase 3 trials ongoing, the drugs are seeing a surge in interest.
Two CAR T-Cell Therapies Greenlighted in Europe
Jef Akst | Aug 28, 2018 | 2 min read
Cancer treatments from Novartis and Gilead earn approval from EU regulators, but a first pass by the UK’s state-funded health service finds CAR T is too expensive. 
Epigenetic Cancer Therapy Clears Phase I
Tracy Vence | Apr 7, 2014 | 2 min read
Investigational drug that inhibits proteins involved with epigenetic regulation shows activity against certain blood cancers in an early-stage clinical trial.

Run a Search

ADVERTISEMENT